Industry News
Pharmaceutical Industry News
Among a string of licensing deals…
Among a string of licensing deals from the week, Takeda's tie-up with Innovent stole the show. Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies. Asian biopharmas
Too old for pediatrics, too young…
Too old for pediatrics, too young for geriatrics - young adults with cancer are falling through the cracks. Here’s how we fix it.
In a new white paper, Havas Lynx…
In a new white paper, Havas Lynx lays out ways in which pharma marketers can—and should, according to the health comms agency—use their platforms to battle rampant misinformation.
Even as Roche executives on…
Even as Roche executives on Wednesday espoused confidence in the company’s resilience and growth potential over the next several years, a mix of exchange rate fluctuations and lackluster pharmaceutical sales led to a worse-than-expected third
Dermatology specialist Galderma…
Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than $650 million through 2030 as it taps domestic contractors to produce newly approved Nemluvio and other skincare treatments
Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.
Cambrex revealed plans to spend…
Cambrex revealed plans to spend $120 million to expand its Iowa manufacturing operations on the heels of a report last month that its owner was seeking a sale.
Cardiovascular Benefits of Wegovy Extend Beyond Weight Loss, Study Shows
An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took Wegovy.
We’re at a tipping point in…
We’re at a tipping point in Alzheimer's disease, with new treatments, multiple validated targets and advanced CNS delivery methods converging.
Nephron Pharmaceuticals’…
Nephron Pharmaceuticals' manufacturing facility in West Columbia, South Carolina, is still running afoul of the FDA. In its most recent Form 483 report, the agency has cited several problems that were evident in an August
Johnson & Johnson is taking…
Johnson & Johnson is taking flight with the New York Jets, joining the NFL team’s roster in a multiyear agreement as its official medical innovation sponsor.
CDx innovation is reshaping…
CDx innovation is reshaping precision oncology—discover how decentralized testing is bringing diagnostics closer to patients.
Merck KGaA plans to discontinue…
Merck KGaA plans to discontinue operations at its production plant in Arklow, Ireland, “by the end of 2028,” a company spokesperson confirmed to Fierce Pharma. The decision follows a strategic review of the products made
Moderna is backing the American…
Moderna is backing the American Lung Association’s call for people with lung diseases to get vaccinated for the upcoming respiratory virus season.
Novartis has filed suit against…
Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.
With plans to pay $2.1 billion to…
With plans to pay $2.1 billion to acquire its Dublin, Ireland, neighbor Avadel Pharmaceuticals, Alkermes is hoping to gain an immediate growth driver in narcolepsy drug Lumryz. But perhaps more importantly, the deal lays the
Novavax will remain headquartered…
Novavax will remain headquartered at another location nearby in Maryland as AstraZeneca takes over its former corporate headquarters in Gaithersburg.
The White House is preparing a…
The White House is preparing a probe to explore whether any U.S. trade partners aren’t paying enough for medicines, the Financial Times reported Wednesday. Unlike the administration’s previous investigation into the national security implications of
How Testosterone Is Giving Middle-Aged Women the Best Sex of Their Lives
There is no F.D.A.-approved testosterone product for women. Insurance won’t cover it. Many doctors won’t prescribe it. It’s become a cultural phenomenon.
The FDA’s recent barrage of…
The FDA’s recent barrage of letters calling out alleged violations of federal pharma marketing rules poses a challenge to drugmakers. Ad agency Real Chemistry is applying AI to the task.